Nitric oxide (NO) 
Introduction
Nitric oxide (NO) , a gas that was once believed to be present only in the atmosphere, is produced in human tissues by the enzyme nitric oxide synthase (NOS), with L-arginine as the substrate.I Thu s far, two form s of this enzyme have been identi fied : constitutive NOS (eNOS), which is expressed constantly reg ardless of environmental conditions, and inducible (type 2) NOS (iNOS), which is express ed only as a reaction to endotoxins and infl ammatory med iators.
Constitutive NOS can be classified according to its site In the inducible form, which is calcium-calmodulinindependent , activation by proinflammatory cytokines and endot oxins results in up to a 1,000-fold increase in NO production comp ared with the eNOS form. Inducible NOS is the result of stimulation by gene tran scription, prob ably via nuclear factor-kappa B; this process can be inhibited by glucocorticoids.' After induction, the increase in NO production lasts for hours and sometimes continues for day s.' Lundberg et al first reported that the dominant NOS activity in nasal mucosa is calciumdependent eNOS and the dominant acti vity in sinu s mucosa is calc ium-indep endent iNOS. 4 However, other s have found iNOS expression in nasal biop sy and scraping specimens obtained from patients with allergic rhiniti s, viral rhinitis, and chron ic rhinitis."?
The presence of endo genou s NO in the exhaled breath of anim als and hum ans was first described by Gustafsson et al in 199 1. 8 Five years later , Lundberg reported that the prim ary production site of exhaled NO is the upper airways." In 2000, Silkoff et al reported that NO is a marker of airway inflammation.'? Indeed, during the past dec ade, several studies have found that patients with allergic rhiniti s or asthma have increased amounts of exhaled and nasal NO .I I -18 In patient s with allerg ic rhinitis, increased iNOS expres sion caused by the release of proinflamm atory cytokines in the upper and lower respiratory tract mucosae has emerged as a possible cause of increased NO levels. Studies of humarr-" and murine" lung epithelial cells have demon strated that cytokines can induce lung epithelial iNOS expression. Robbins et al also demonstrated that iNOS express ion in both human and murine lung epith elial cells can be attenuated by dexamethas one. P' " They wrote that this effect is prob ably the result of a reduction in iNOS mRNA at the tran scriptional level." In this article, we describe our investigatio n of the effect that topical nasal steroid treatment has on VNO in a patient with symptomatic allergic rhinitis.
Materials and methods
One ofthe authors (C.V.), a nonsmoking 41-year old man, volunteered to serve as the subject for this study. Nasal examination revealed that he had a mild nasal septal deviation that obstructed less than 25% of the left nasal passage. Skin -prick testing was positive for dust mites (Dermatophagoides pteronyssinusi and certain grasses (Kentucky blue, orchard, and redtop) . During the study, the patient did not use avoidance measures to reduce his exposure to dust mites and pollen.
On the morning of June 25, 2002 , when the patient's allergic symptoms were at peak levels, he began to administer fluticasone nasal spray, at 100 ug per nostril once a day immediately follo wing his NO measurement. He continued taking flutic asone for 4 weeks. In the greater Pittsburgh area that year, the seaso nal increase in grass pollen levels began in the middle of May and continued through the end of July.
The patient 's NO levels were measured with a rapidresponse chemiluminescent Sievers 280 NOA analyzer (Sievers Instruments; Boulder, Colo.). The analyzer pump 's sampling flow was 0.2 Llmin. A two-p oint calibration was performed daily, first with air passed through an NO scrubber tube that contained KMn0 4 and activated charcoal to zero and then with certified NO gas (45 parts per million) for the span (Datex-Ohmeda; Madison, Wis.). Ambient NO was recorded before each measurement. The NO analyzer signa l outp ut was fed into a computer data acquisition program (NO analysis softw are for the NOA 280, version 3.00 PNE; Sievers Instruments). The program featured a real-time display of NO vs time that was written directly into the computer's hard disk as a data file, and results were displayed as a graphic output. The components of the sampling device were a latex nasal olive (ENTsol Adapter; Kenwood Therapeutics; Fairfield, N.J.), a filter (Resp-Bac; Medicomp; Princeton, Minn.), a respirator tube (Airlife; Allegiance Healthcare; McGaw Park , 111.), and a gas-sampling connector with a midstream sampling port (Respiratory Support Products; Irvine, Calif.) (figure 1).
After the olive was gently inserted into the patient ' s naris, he closed his velum by holding his breath. Room air entered through the left nostril and was aspirated from the right nostril at a constant rate of 5 Llmin . The flow through the nasal cavities was created by suction and continuously monitored with a highly accurate flow meter (Aalborg Instruments; Monsey, N.Y.). NO was sampled through a side port just distal to the tube. After an interval of I to 2 minutes, the procedure was repeated on the other side. On each measurem ent day, on-line nasal NO measurements were taken between 9 a.m. and 10 a.m. from both sides of the nose following a l-hour period of adjustment to the environment. After 10 to 20 seconds of breathholding, a plateau of NO level was reached. Extrapolation of the mean by the software from this plateau was accepted as the on-line measurement value . To calcu late the V NO ' the ambient NO values were subtracted from the mean values of both sides of the nose, and the resulting values were multiplied by the aspiration flow rate (5 LI min).
The patient filled out a symptom ques tionnaire once every measurement day to rate the degree of nasal itching, sneezing, nasal discharge, congestion, and facial pain or pressure. Symptom s were scored as 0 (no symptoms), 1 (mild), 2 (moderate), and 3 (severe). Tot al and specific symptom scores were calculated and recorded for each day. Each day' s grass pollen counts were obtained from the Children' s Hospital of Pittsburgh' s pollen count station as often as possible (the station was closed on weekends and holidays).
In all, 14 nasal NO measurements were obtained before steroid treatment and 14 afterward; post-treatment measurements began 10 days following the initiation of treatment. The Student' s t test was used for statistical analysis.
Results
During the pretre atment phase, the patient' s nasal symptoms related to allergic rhiniti s were prominen t and his V NO levels were substantial (mean V NO : 989.9 nl/min). At the post-treatment evaluations, nasal symptom scores and V NO levels (mean V NO : 787.7 nl/min) were reduced ( figures 2 and 3) . The 20.4 % difference between the pre-and post-treatment V NO levels was statistically significant (p<0 .01).
Discussion
Topical nasal steroids are one of the most effective treatments for allergic rhinitis. As expected, our patient experienced a marked decrease in nasal symptoms and a significant decrease in his mean VNO level following steroid therapy. Although Lundberg et al" found that topical nasal steroids had no effect on nasal NO levels , others reported the opposite. Baraldi et al found that nasal steroids reduced elevated nasal NO levels in patients with allergic rhinitis." Dillon et al" and Kharitonov et aF2 also reported a reduction in nasal NO levels after steroid treatment. However, a common limitation of these studies was their suboptimal NO sampling techniques.
Springall et al found an incre ased expression of iNOS in the pulmonary epithelium of asthma patients, and they reported that this expression was reduced by corti costeVolume 82, Number 8 roid treatment." They concluded that this reduction might be the result of a resolution of inflammation and the subsequent reduction in the release of cytokines that stimulate iNOS expression. The same group of researchers also found that the expression ofiNOS in nasal mucosa was increased in patients with allergic rhinitis. >' This increased expression is possibly a result of an increase in the release of cytokines in sinonasal mucosa, which might explain the high VNO levels seen -in allergic rhinitis patients.
The decline in V NO in our patient supports the observation that iNOS, which can be inhibited by steroids, contributes to nasal NO production." Even so, the fact that the decrease was only 20.4 % indicates that a significant amount of nasal NO production appears to be resistant to steroid treatment. This resistance might be attributable to the production of NO by cNOS or the production of NO in sinus mucosa , neither of which should be affected by nasal steroid sprays. Still, we cannot rule out the possibility that an incomplete suppression of iNOS is attributable to an inadequate corticosteroid dosage.
To minimize the probable topical effects that steroidspray vehicles have on nasal V NO levels, our patient used the spray immediately after nasal NO measurements were obtained. As a result, the interval of almost 24 hours was likely to have mitigated any effects of the vehicle. One might argue that the decrea se in our patient's V NO levels was related to the decrease in gras s pollen concentration during the treatment period , but his VNO levels were ju st as high before the onset of the grass pollen season as they were during the pollen season.
In conclusion, V NO measurement is a simple, noninv asive procedure. Changes in V NO can serve as a marker of sinonasal inflammation and can be used to monitor therapeutic efficacy. We belie ve that our preliminary study had one advantage over other studies l8 • 2 1,22 in that we used an optimal sampling technique and standardized measurin g and reporting methods." We hope our findings and methods will be put to the test in larger group s of patient s. 
